STS 2019: Can Mutations Predict Survival After Pulmonary Metastasectomy for Colorectal Cancer?
Posted: Thursday, March 28, 2019
According to a study presented at the 2019 Society of Thoracic Surgeons (STS) Annual Meeting in San Diego, mutations may play an important role in survival and disease recurrence in patients undergoing pulmonary metastasectomy for colorectal cancer. Erin Corsini, MD, MS, and colleagues at The University of Texas MD Anderson Cancer Center, Houston, suggested that the mutations KRAS and TP53 were valid predictors of disease-free survival following surgery and APC may be protective for pulmonary disease–free survival.
The study identified 130 patients who underwent pulmonary metastasectomy for colorectal cancer. Analyses were based on patients with KRAS (n = 130; 57%), TP53 (n = 83; 64%), and APC (n = 68; 52%) mutations.
After a median follow-up of 33.2 months, all 3 mutations were valid predictors of overall survival. Specifically, KRAS (P = .01) and TP53 (P = .02) mutations were significant predictors of disease-free survival, whereas APC and TP53 effectively predicted pulmonary disease–free survival. KRAS and TP53 increased the hazard of death, whereas APC may be protective for pulmonary disease–free survival. After surgery, 67% (n = 87) of patients experienced disease recurrence. Of these patients, 58% (n = 75) had at least a single lung recurrence.
Other than genetic mutations, the authors did not identify additional variables that predicted overall or disease-free survival. However, factors including age and colorectal nodal disease increased the hazard of death, whereas gender appeared to be a valid predictor of pulmonary disease–free survival.
Disclosure: The study authors’ disclosure information can be found at sts.org.
